---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-21-056469"
form_type: "8-K"
ticker: "ADIL"
cik: "0001513525"
company_name: "ADIAL PHARMACEUTICALS, INC."
filed_at: "2021-11-03T23:59:59+00:00"
generated_at: "2026-06-28T13:54:20.156592+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Adial appoints former Indivior CFO Cary Claiborne to board of directors

## Summary
- Cary J. Claiborne appointed to Adial's board, expanding board to seven members.
- He previously served as CFO and board member of Indivior PLC, a specialty pharma company.
- Received an option for 60,000 shares at $3.15, vesting monthly over 36 months.
- CEO Stilley noted his experience will aid preparations for Phase 3 trial completion and potential commercial launch.
- Claiborne's background includes CFO roles at Sucampo Pharmaceuticals and Osiris Therapeutics.

## SEC filing metadata
- accession: 0001213900-21-056469
- form_type: 8-K
- ticker: ADIL
- cik: 0001513525
- company_name: ADIAL PHARMACEUTICALS, INC.
- filed_at: 2021-11-03T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1513525/000121390021056469/0001213900-21-056469-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1513525/000121390021056469/ea149870-8k_adialpharm.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-21-056469
- JSON: https://secwatch.observer/filing/0001213900-21-056469.json
- Plain text: https://secwatch.observer/filing/0001213900-21-056469.txt

## Key facts
- Executive change
  Cary J. Claiborne was appointed as director at ADIAL PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: director
  source text: On November 2, 2021, Cary J. Claiborne joined the board of directors (the “Board”) of Adial Pharmaceuticals, Inc. (the “Company”) to serve as a Class I member of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1513525/000121390021056469/0001213900-21-056469-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.